Freeline Therapeutics (Nasdaq: FRLN), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases rang the Nasdaq Opening Bell remotely from across the country.

In honor of the occasion, Theresa Heggie, CEO, rang the Opening Bell in a virtual bell ringing ceremony.